Improving Clinical Risk Stratification at Diagnosis in Primary Prostate Cancer: A Prognostic Modelling Study

1. World Health Organization. Global Health Observatory (GHO) data: cancer mortality and morbidity. 2016 [cited 27 May 2016]. Available: http://www.who.int/gho/ncd/mortality_morbidity/cancer_text/en/.

2. Mistry M, Parkin DM, Ahmad AS, Sasieni P. Cancer incidence in the United Kingdom: projections to the year 2030. Br J Cancer. 2011;105:1795–1803. doi: 10.1038/bjc.2011.430 22033277

3. Ke Zhou C, Check DP, Lortet-Tieulent J, Laversanne M, Jemal A, Ferlay J, et al. Prostate cancer incidence in 43 populations worldwide: an analysis of time trends overall and by age group. Int J Cancer. 2015;138:1388–1400. doi: 10.1002/ijc.29894 26488767

4. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012;61:1079–1092. doi: 10.1016/j.eururo.2012.02.054 22424666

5. D’Amico AV, Whittington R, Malkowicz SB, Fondurulia J, Chen M-H, Kaplan I, et al. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol. 1999;17:168–172. 10458230

6. Thompson I, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cookson MS, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007;177:2106–2131. 17509297

7. National Institute for Health and Care Excellence. Prostate cancer: diagnosis and treatment. NICE guidelines [CG175]. London: National Institute for Health and Care Excellence; 2014.

8. Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D’Amico AV, et al. Prostate cancer, version 2.2014. J Natl Compr Canc Netw. 2014;12:686–718. 24812137

9. Reese AC, Pierorazio PM, Han M, Partin AW. Contemporary evaluation of the National Comprehensive Cancer Network prostate cancer risk classification system. Urology. 2012;80:1075–1079. doi: 10.1016/j.urology.2012.07.040 22995570

10. Hernandez DJ, Nielsen ME, Han M, Partin AW. Contemporary evaluation of the D’Amico risk classification of prostate cancer. Urology. 2007;70:931–935. 18068450

11. Epstein JI, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, Magi-Galluzzi C, et al. A contemporary prostate cancer grading system: a validated alternative to the Gleason score. Eur Urol. 2016;69:428–435. doi: 10.1016/j.eururo.2015.06.046 26166626

12. Greenberg DC, Wright KA, Lophathanon A, Muir KR, Gnanapragasam VJ. Changing presentation of prostate cancer in a UK population—10 year trends in prostate cancer risk profiles in the East of England. Br J Cancer. 2013;109:2115–2120. doi: 10.1038/bjc.2013.589 24071596

13. Falzarano SM, Magi-Galluzzi C. Prostate cancer staging and grading at radical prostatectomy over time. Adv Anat Pathol. 2011;18:159–164. doi: 10.1097/PAP.0b013e31820cb506 21326013

14. Cooperberg MR, Pasta DJ, Elkin EP, Litwin MS, Latini DM, Du Chane J, et al. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol. 2005;173:1938–1942. 15879786

15. Rodrigues G, Lukka H, Warde P, Brundage M, Souhami L, Crook J, et al. The prostate cancer risk stratification (ProCaRS) project: recursive partitioning risk stratification analysis. Radiother Oncol. 2013;109:204–210. doi: 10.1016/j.radonc.2013.07.020 24231239

16. Joniau S, Briganti A, Gontero P, Gandaglia G, Tosco L, Fieuws S, et al. Stratification of high-risk prostate cancer into prognostic categories: a European multi-institutional study. Eur Urol. 2015;67:157–164. doi: 10.1016/j.eururo.2014.01.020 24486307

17. Loeb S, Montorsi F, Catto JW. Future-proofing Gleason grading: what to call Gleason 6 prostate cancer? Eur Urol. 2015;68:1–2. doi: 10.1016/j.eururo.2015.02.038 25769986

18. Department of Health. Delivering the cancer reform strategy. 2010 Nov 18 [cited 27 May 2016]. London: National Audit Office. Available: http://www.nao.org.uk/wp-content/uploads/2010/11/1011568.pdf.

19. Newson RB. Comparing the predictive power of survival models using Harrell’s c or Somers’ D. Stata J. 2010;10:339–358.

20. Lambert PC. Estimating and modelling cumulative incidence functions using time-dependent weights [presentation]. 2013 UK Stata Users Group Meeting; 12–13 Sep 2013; London, UK.

21. Dall’Era MA, Albertsen PC, Bangma C, Carroll PR, Carter HB, Cooperberg MR, et al. Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol. 2012;62:976–983. doi: 10.1016/j.eururo.2012.05.072 22698574

22. Godtman RA, Holmberg E, Khatami A, Stranne J, Hugosson J. Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Göteborg randomised population-based prostate cancer screening trial. Eur Urol. 2013;63:101–107. doi: 10.1016/j.eururo.2012.08.066 22980443

23. Lukka H, Warde P, Pickles T, Morton G, Brundage M, Souhami L, et al. Controversies in prostate cancer radiotherapy: consensus development. Can J Urol. 2001;8:1314–1322. 11564274

24. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol. 2003;169:517–523. 12544300

25. Roach M, Lu J, Pilepich MV, Asbell SO, Mohiuddin M, Terry R, et al. Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials. Int J Radiat Oncol Biol Phys. 2000;47:609–615. 10837943

26. Cooperberg MR, Broering JM, Carroll PR. Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. J Natl Cancer Inst. 2009;101:878–887. doi: 10.1093/jnci/djp122 19509351

27. Greenberg DC, Lophatananon A, Wright KA, Muir KR, Gnanapragasam VJ. Trends and outcome from radical therapy for primary non-metastatic prostate cancer in a UK population. PLoS ONE. 2015;10:e0119494. doi: 10.1371/journal.pone.0119494 25742020

28. Reese AC, Cooperberg MR, Carroll PR. Minimal impact of clinical stage on prostate cancer prognosis among contemporary patients with clinically localized disease. J Urol. 2010;184:114–119. doi: 10.1016/j.juro.2010.03.025 20478578

29. Reese AC, Sadetsky N, Carroll PR, Cooperberg MR. Inaccuracies in assignment of clinical stage for localized prostate cancer. Cancer. 2011;117:283–289. doi: 10.1002/cncr.25596 21210472

30. Fraser M, Berlin A, Bristow RG, van der Kwast T. Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancer. Urol Oncol. 2015;33:85–94. doi: 10.1016/j.urolonc.2013.10.020 24768356

31. Boström PJ, Bjartell AS, Catto JW, Eggener SE, Lilja H, Loeb S, et al. Genomic predictors of outcome in prostate cancer. Eur Urol. 2015;68:1033–1044. doi: 10.1016/j.eururo.2015.04.008 25913390

32. Klein EA, Cooperberg MR, Magi-Galluzzi C, Simko JP, Falzarano SM, Maddala T, et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur Urol. 2014;66:550–560. doi: 10.1016/j.eururo.2014.05.004 24836057

33. Cullen J, Rosner IL, Brand TC, Zhang N, Tsiatis AC, Moncur J, et al. A biopsy-based 17-gene genomic prostate score predicts recurrence after radical prostatectomy and adverse surgical pathology in a racially diverse population of men with clinically low- and intermediate-risk prostate cancer. Eur Urol. 2015;68:123–131. doi: 10.1016/j.eururo.2014.11.030 25465337

34. Cuzick J, Stone S, Fisher G, Yang ZH, North BV, Berney DM, et al. Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort. Br J Cancer. 2015;113:382–389. doi: 10.1038/bjc.2015.223 26103570